IGA-CHE Results
Significant skin
clearance1,3
IGA-CHE treatment success at Week 8, ANZUPGO vs cream vehicle3:
• DELTA 1 (N=325/N=162): 22.8% vs 10.5% (P=0.001) • DELTA 2 (N=313/N=159): 32.3% vs 9.4% (P<0.0001)
Primary endpoint
Up to 4x
More patients achieved treatment success†on ANZUPGO vs cream vehicle at Week 16 (DELTA 2)1
Secondary endpoint
as early
as week 4
ANZUPGO showed significantly better results vs cream vehicle3
IGA-CHE=Investigator's Global Assessment for Chronic Hand Eczema (a 5-point assessment scale: 4, severe; 3, moderate; 2, mild; 1, almost clear; 0, clear); TS=treatment success.1,4
†Treatment success was defined as achieving clear (IGA-CHE 0) or almost-clear (IGA-CHE 1) skin in addition to a ≥2-point improvement from baseline IGA-CHE score.1
Itch & pain Results
Quick relief
from itch and pain1,3,5‡
Key secondary endpoints
On ANZUPGO, significantly more patients achieved a ≥4-point reduction in HESD-itch at Weeks 2, 4, 8, and 16, and HESD-pain at Weeks 4, 8, and 16 vs cream vehicle
‡Itch and pain were assessed using the Hand Eczema Symptom Diary (HESD), a self-reported 11-point rating scale designed to measure the 6 CHE signs and symptoms over the past 24 hours.3
§P<0.05 vs cream vehicle for DELTA 1.5
||P<0.05 vs cream vehicle for DELTA 2.5
Itch and pain data
through 16 weeks of treatment with ANZUPGO5,6¶
Secondary endpoints
Change in itch and pain scores vs baseline were observed as early as Day 15,6
Itch data by weeks5
Pain data by weeks5
LIMITATIONS
Data were reported as observed. No conclusions on safety or efficacy should be made based on these results.
Itch and pain data
from initial application through Day 66¶
EXPLORATORY ENDPOINTS
Change in itch and pain scores vs baseline were observed as early as first dose6
Itch data by day (pooled analysis)
Pain data by day (pooled analysis)
LIMITATIONS
Change in mean HESD-itch and -pain had weekly prespecified endpoints from baseline through Week 16 in DELTA 1 and 2. This pooled analysis was not prespecified and not adjusted for multiplicity. Conclusions should be made with caution.
¶Itch and pain were assessed using the Hand Eczema Symptom Diary (HESD), a self-reported 11-point rating scale designed to measure the 6 CHE signs and symptoms over the past 24 hours.3
Clear or almost clear skin through 52 weeks with ANZUPGO used as needed7
DELTA 3
Open-label extension
LIMITATIONS
The efficacy data presented here is derived from an open-label extension trial designed primarily to assess safety. Conclusions should be made with caution.
Itch & Pain Data
through 52 weeks WITH ANZUPGO USED AS NEEDED8
HESD ITCH REDUCTION ≥4#
DELTA 3
Open-label extension
HESD PAIN REDUCTION ≥4**
DELTA 3
Open-label extension
LIMITATIONS
The efficacy data presented here is derived from an open-label extension trial designed primarily to assess safety. Conclusions should be made with caution.
HESD=Hand Eczema Symptom Diary.
#Only includes patients with parent trial baseline itch score ≥4. Missing data was imputed as non-response.
**Only includes patients with parent trial baseline pain score ≥4. Missing data was imputed as non-response.